The latest updates from OTCMarkets | Not displaying properly? Click here
October 12, 2017
OTC Markets Group and the Canadian Securities Exchange to Announce Strategic Alliance

This month, OTC Markets Group and the Canadian Securities Exchange (CSE), a Canadian listing exchange recognized as a Qualified Foreign Exchange in the U.S., announced the upcoming launch of a strategic alliance that will offer a new program for issuers looking for an efficient IPO experience in Canada and cost-effective access to North American investors.

This first-of-its-kind North American capital and visibility solution will offer issuers the CSE's IPO listing and trading services, coupled with the enhanced U.S. disclosure distribution and secondary trading on OTC Markets' OTCQX Best Market/OTCQB Venture Market. The resulting combination will offer an efficient alternative for international companies seeking to raise capital, build global investor awareness and have their shares trade in two of the world's largest financial markets. Both OTC Markets Group and the CSE emphasize simple processes and fixed fee structures that remove much of the cost, time and complexity typically associated with going public on an exchange. This cooperative effort is positioned to introduce foreign issuers to North American capital formation resources and secondary market liquidity.

Continental Stock Transfer & Trust Company Joins OTC Markets' Transfer Agent Verified Shares Program

In October, Continental Stock Transfer & Trust Company became the 13th transfer agent to participate in OTC Markets' Transfer Agent Verified Shares Program.

Launched in October 2016, the Transfer Agent Verified Shares Program is an initiative designed to provide investors with current and reliable share data on OTCQX, OTCQB and Pink securities. The program enables stock transfer agents to report their clients' share data, including authorized and outstanding shares, to OTC Markets Group on a regular basis via a secure, electronic file transfer.  Share data provided by transfer agents is displayed on alongside a "Verified" logo, indicating the information is reliable and trustworthy. This data is also disseminated through OTC Markets Group's market data products to investors and broker-dealers. Learn More.

Contact Andy Kyzyk, VP of Advisor Relations, at for more information.

3 Strong Points for SME Markets

OTC Markets Blog: Earlier in 2017, The World Federation of Exchanges released their report highlighting major barriers of entry to equity market financing for Small and Medium Enterprises (SMEs). We find parallels between key recommendations and the unique public market framework we have built at OTC Markets Group to help smaller public companies succeed. Read the full report.

Blue Sky Recognition - 26 States

Hawaii now recognizes the OTCQX and OTCQB markets for for the purposes of each state's "Blue Sky Manual Exemption." 26 states recognize OTCQX and 23 states recognize OTCQB. We are continuing our campaign to gain national Blue Sky recognition for the markets.

Community Spotlight

Erik Kinnman, CEO of
Neurovive Pharmaceutical AB (OTCQX:

"Our business model now has a two-pronged strategy – in our core business we aim to take projects concerning rare diseases to the market, and for common diseases our goal is to bring projects to the preclinical stage for out-licensing. This allows for a more diversified project portfolio, with the possibility of both near-term revenues as well as near and long-term substantial value creation."


Read the full interview.

OTC Markets Group (OTCM): Tell us about Neurovive Pharmaceutical. What do you want U.S. investors to know?

Erik Kinnman: NeuroVive is a Swedish specialist pharmaceutical company with research and development focused primarily on mitochondrial medicine and diseases in which the mitochondria are involved. Properly functioning mitochondria are essential to our bodies’ energy production, and cell protection and survival. Mitochondrial diseases are often genetic and chronic disorders that can cause symptoms such as muscle weakness, visual impairment, poor growth and delayed development. Mitochondrial diseases affect 1 in 5000 people, but treatments are scarce and are often classified as orphan drugs. The secondary progress of nerve cell damage in Traumatic brain injury (TBI) is related to the function of mitochondria. There are some 3 million TBI patients each year in the US and Europe, out of which 15% are moderate to severe.

We are currently working on a range of projects. A TBI phase II PoC clinical study in the NeuroSTAT project is underway, and KL1333 for genetic mitochondrial disease is in phase I clinical development. These are both orphan indications in areas of high unmet medical need. The furthest advanced preclinical program, NV556 for NASH, has shown convincing effects in fibrosis and an outlicensing process has been initiated.

OTCM: What were your major accomplishments in the past year?

Mr. Kinnman: We have reached several important milestones thus far this year. We have received positive results in our TBI-project NeuroStat, in the experimental TBI-studies at the University of Pennsylvania and the phase IIa Copenhagen Head Injury Ciclosporin Study (CHIC). We acquired the rights to the clinical stage candidate drug KL1333 for genetic mitochondrial disorders. In preclinical studies KL1333 has demonstrated increased mitochondrial energy output, reduced lactate accumulation, diminished the formation of free radicals, and to have long-term beneficial effects on energy metabolism through mitochondrial biogenesis. Our NASH project NV556 and our HCC project NVP024 have both returned positive preclinical results.

We have also welcomed Esousa, a US-based family office specialized in emerging growth companies, as a new investor in NeuroVive. On the personnel side, we have added Mark Farmery as our new VP of Business Development, and Daniel Schale as our new Director of Communications.

OTCM: How does Neurovive differentiate itself from its competitors and what is your growth strategy?

Mr. Kinnman: NeuroVive has recently updated its business model to adapt to developments in the pharmaceutical and life science industries. Our business model now has a two-pronged strategy – in our core business we aim to take projects concerning rare diseases to the market, and for common diseases our goal is to bring projects to the preclinical stage for out-licensing. This allows for a more diversified project portfolio, with the possibility of both near-term revenues as well as near and long-term substantial value creation.

OTCM: Neurovive joined OTCQX in June 2016. How are leveraging OTCQX as part of your U.S. IR program?

Mr. Kinnman: As we increase our presence in the US capital markets, trading on OTCQX will help us in our IR efforts, aimed at attracting both US retail and small to mid-size institutional investors. With our significant collaborations with US-based research institutions, such as University of Pennsylvania and the Children’s Hospital of Philadelphia, it is only natural that we offer US based investors the opportunity to invest in our company.

Click to close.

easyJet Plc

OTCQX Video Series: Jason Paltrowitz, OTC Markets Group EVP, caught up with Stuart Morgan, Head of Investor Relations for easyJet Plc (OTCQX: ESYJY) to talk about easyJet's business model and its strategy for growth in Europe's primary airports. Watch now.

Monthly Trade Summary - September 2017
Market Designations Number
of Securities*
$ Volume
Monthly $ Volume
per Security
YTD $ Volume*
OTCQX 415 $4,113,005,773 $9,910,857 $33,553,443,735
OTCQB 981 $1,478,804,082 $1,507,445 $15,663,604,245
Pink 8,901 $13,513,013,747 $1,518,145 $115,872,017,852
Total 10,297 $19,104,823,603 $1,855,377 $165,089,065,833

*Data as of September 30, 2017


EQS Germany Roadshow – Munich, Germany (September 29, 2017) | Frankfurt, Germany (October 5, 2017)

OTCQX Virtual Investor Conference – Webcast (October 5, 2017)

MicroCap Investor Conference – New York, NY (October 5, 2017)

OTCQX Annual Issuers Forum – Toronto, Canada (October 18, 2017)

Webinar: Accessing Investors: Best Practices on the Road – Webinar (October 19, 2017)

STA Annual Conference – Manalapan, Florida (October 23-26, 2017)

Tri-State Banking & Capital Markets Forum – Wayne, Indiana (November 1, 2017)

Hovde 2017 Fast Forward Conference – Phoenix, AZ (November 5-7, 2017)

2017 STANY International Reception and Holiday Party – New York, NY (November 16, 2017)

World Funding Summit & Capital Expo – Los Angeles, CA (November 17-18, 2017)

LD Micro: 10th Annual Main Event – Los Angeles, CA (December 5-7, 2017)

Vancouver Resource Investment Conference – Vancouver, Canada (January 21-22, 2018)

Access North American Capital Markets – Singapore (January 23-24, 2018)

NOBLE Conference – Ft. Lauderdale, FL (January 29-30, 2018)

Please contact for more information.

OTCQX Virtual Investor Conference - Archived Webcast

Listen to presentations on-demand from our October 5th OTCQX Virtual Investor Conference featuring 15 U.S.-based companies traded on the OTCQX Best Market. OTCQX company CEOs and top executives discussed their businesses and investment stories and answered questions from investors. Watch the presentations.


Trinity Capital Corporation Commences Trading On OTCQX And Announces DTC Eligibility – Los Alamos Daily Post (September 11, 2017)

Weyland Tech Begins Trading on the OTCQX – (September 12, 2017)

Why LANB is now trading on OTCQX – Albuquerque Business First (September 21, 2017)

OTC Markets Group Executive Vice President Jason Paltrowitz on Equity Crowdfunding & IPOs – Investor Town Hall Show (September 29, 2017)

OTC Markets Group 2017 Small Cap Survey – October 2017 MaloneBailey podcast (October 1, 2017)

OTC Markets Group Welcomes Australia's Digital Banking Platform Change Financial to OTCQX – Crowdfund Insider (October 2, 2017)

OTC Markets Group, Canadian Securities Exchange announce alliance – Bankless Times (October 5, 2017)

New OTCQX and OTCQB Companies

Welcome to the companies that joined the OTCQX Best Market and the OTCQB Venture Market in September 2017.

The OTCQX Best Market
Ascendant Resources Inc. (OTCQX: ASDRF)
Beleave Inc. (OTCQX: BLEVF)
Covalon Technologies Ltd. (OTCQX: CVALF)
Dragon Jade International Ltd. (OTCQX: DGJI)
Leagold Mining Corporation (OTCQX: LMCNF)
Nighthawk Gold Corp. (OTCQX: MIMZF)
Torq Resources Inc. (OTCQX: TRBMF)
Trinity Capital Corporation (OTCQX: TRIN)
Weyland Tech Inc. (OTCQX: WEYL)

The OTCQB Venture Market
Antibe Therapeutics, Inc. (OTCQB: ATBPF)
AppSoft Technologies, Inc. (OTCQB: ASFT)
Chemistree Technology Inc. (OTCQB: CHMJF)
Delcath Systems, Inc. (OTCQB: DCTH)
Diamcor Mining Inc. (OTCQB: DMIFF)
Dthera Sciences (OTCQB: DTHR)
FalconStor Software, Inc. (OTCQB: FALC)
First Priority Tax Solutions Inc. (OTCQB: FPTA)
Gunpowder Capital Corp. (OTCQB: GNPWF)
Maricann Group Inc (OTCQB: MRRCF)
MGT Capital Investments, Inc. (OTCQB: MGTI)
MGX Minerals Inc (OTCQB: MGXMF)
Nevada Exploration Inc. (OTCQB: NVDEF)
Plateau Uranium Inc. (OTCQB: PLUUF)
PreveCeutical Medical Inc. (OTCQB: PRVCF)
Stina Resources Ltd. (OTCQB: STNUF)
Tower One Wireless Corp (OTCQB: TOWTF)
Triumph Gold Corp (OTCQB: NFRGF)
Verde Agritech PLC (OTCQB: AMHPF)
VirtualArmour International Inc. (OTCQB: VTLR)
WhereverTV Broadcasting Corp. (OTCQB: TVTV)

Graduates to an Exchange Listing

The following companies graduated to an exchange listing in September 2017.


Graduated from the OTCQB Venture Market
Fennec Pharmaceuticals, Inc. (NASDAQ: FENC)